PROBIAL Vision UVEA

PROBIAL® Vision UVEA is a probiotic supplement specifically formulated with three Bifidobacterium strains: Bifidobacterium longum 04, Bifidobacterium bifidum BB01, and Bifidobacterium breve BR03. It is designed to reduce the number of recurrences of Acute Anterior Uveitis (AAU).

Uveitis refers to a group of inflammatory diseases affecting the intraocular uveal tissues and adjacent structures, potentially leading to sight-threatening inflammation [1]. In the United States, uveitis is estimated to contribute to up to 15% of blindness cases [2]. The involvement of gut microbiota in the pathogenesis of uveitis is suggested through several mechanisms, including antigenic mimicry, impaired microbiome-dependent immune homeostasis due to dysbiosis, disruption of intestinal barrier function related to dysbiosis, and the migration of gut mucosal-associated lymphocytes to peripheral sites [3].

A case study highlighted the potential benefits of PROBIAL® Vision UVEA in treating uveitis [4]. In this study, a woman with a three-year history of acute anterior uveitis in the right eye underwent treatment with a combination of topical steroids, atropine, and oral PROBIAL® Vision UVEA for one year. This case is the first of its kind reported in the literature using this therapeutic approach. The treatment led to decreased ocular inflammation, improvement in best-corrected visual acuity (primary outcome), and allowed for the discontinuation of steroids and atropine in the following months. During a one-year follow-up period, no recurrence or ocular inflammation was observed in the fellow eye.

The proposed mechanism of action for PROBIAL® Vision UVEA involves the modulation of cellular immunity, particularly the regulation of T cells and IL-17, which may inhibit the initiation of the inflammatory cascade leading to uveal inflammation.